Investment will support investigation of Mission’s small molecule drug MTX325 in patients with early-stage Parkinson’s disease Marks latest step in Mission’s relationship with The Michael J. Fox Foundation (MJFF), after MJFF awarded Mission preclinical research grants in 2017 and 2021,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.